Longevity
The Fatty Acid Signature of Healthy Aging to 80
A 15,000-person cohort sharpens which fats in your bloodstream travel with healthspan — not just the years, but the years lived free of major disease.
cardiovascular
Peptides
Exenatide's Heart Win Isn't Just the Sugar or the Scale
A fresh post hoc dive into EXSCEL says the cardiovascular payoff from a once-weekly GLP-1 isn't fully explained by better A1c, blood pressure, or bodyweight. Something else is doing work.
Metabolic Health
Beyond Blood Sugar: How GLP-1 Drugs Rewire the Cardiometabolic Network
A new gene-metabolite map suggests incretin-pathway drugs act on a web of cardiovascular and metabolic systems — not just glucose. Here's what that means for patients in 2026.
Longevity
The Exposome: Why Your ZIP Code May Outweigh Your Supplement Stack
A new review in Atherosclerosis argues that the air you breathe, the noise outside your window, and the climate you live in may shape cardiovascular risk more than the contents of your medicine cabinet.
Peptides
GLP-1s Go Cardio: What a New Meta-Analysis Says About Heart Attack Risk
A 109,000-patient meta-analysis sharpens the case that GLP-1 receptor agonists are cardiometabolic drugs, not just weight-loss tools — with concrete numbers on who actually benefits.
Peptides
The New GLP-1 Frontier: Combo Stacks, Cardio Synergy, and the Oral Pill Race
GLP-1s aren't just a shred-cycle headline anymore. The next wave — liver-targeting combos, cardiovascular synergy with training, and oral delivery — is rewriting what these peptides can do.
Metabolic Health
Lifestyle Still Wins: The 2025 Case for Diet, Exercise and the Metabolic Trio
A major Herz review reaffirms that Mediterranean eating, structured movement and smoking cessation move the endpoints that matter — a useful corrective in the GLP-1 era.
Medical Research
Female Cardiovascular Physiology Is Not Male Physiology — And the Lifespan Data Are Finally Arriving
A new Physiology review maps how sympathetic nerves, baroreflexes and blood pressure shift across the menstrual cycle, pregnancy and menopause — and where the science still goes dark.
Medical Research
Beyond LDL: The New Lipid Targets Reshaping Cardiovascular Risk
Human genetics is guiding a fresh class of lipid drugs — Lp(a) inhibitors and lipoprotein-lipase activators — aimed at the residual heart risk statins can't reach.
Metabolic Health
Beyond Weight Loss: What the Latest GLP-1 Evidence Says About Liver, Kidney, Heart, and Cost
Fresh 2025 reviews map semaglutide's reach into fatty liver disease, cardiovascular risk, kidney protection — and the economics of treating obesity at scale. The signals are real, but the picture is still filling in.